Candidemia In Hospitalized Patients In Saint-Petersburg | CMAC

Candidemia In Hospitalized Patients In Saint-Petersburg

Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):15-21

​ Klimko N.N., Bogomolova T.C., Kolb Z.K., Saturnov A.V., Perekatova T.N., Belogurova M.B., Lebedev V.F., Shliapnikov S.A., Petrova E.M., Sokirski E.K., Zuzgin I.S., Shneyder T.V., Karyagin I.E., Edelstain V.A., Timokhovskaya G.J., Kolbin A.S., Pestova L.A., Ivanuk F.V.
candidemia acute disseminated candidosis Candida fluconazole amphotericin B
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):15-21

Abstract

During prospective study carried out in 1998–2000 risk factors, spectrum of pathogens, treatment options and mortality in 45 episodes of candidemia in 45 patients from 16 Saint-Petersburg’s hospitals have been analyzed. Majority (84%) of patients with candidemia were hospitalized in intensive care units (ICU), 13% – in therapeutic wards and 3% – in surgical one. The main reasons for admission in ICU were operations (36%), neoplasms (33%) and traumas (13%). Etiologic agents of candidemia were Candida parapsilosis (32%), C.albicans (28%), C.tropicalis (10%), C.glabrata (8%), С.guilliermondii (2%), C.famata (2%), C.zeylanoides (2%), C.rugosa (2%), С.krusei (2%), C.lusitaniae (2%), Candida sp. (10%). Two and more species of Candida spp. has been isolated from blood in 9% of patients. Localized lesions in different organs have been found in 38% of patients. Antifungal therapy was administered to 60% of patients; intravenous catheters were removed in 68%. Total mortality within 30 days after diagnosis of candidemia was 49%. Mortality in patients who received antifungal therapy was 37%, in patients without specific therapy – 72%. Mortality after removal of intravenous catheter was 35%, without removal – 92%.

  • 1. Beck Sague C., Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. J Infect Dis 1993; 167:1247-51.
  • 2. Jarwis W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20:1526-30.
  • 3. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27(5): 887-92.
  • 4. Vincent J.L., Anaissie E., Bruining H., et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. J Intensive Care Med 1998; 24(3):206-16.
  • 5. Vincent J.L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274(8):639-44.
  • 6. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol 2000; 17:73-81.
  • 7. Ronveaux O., Jans B., Suetens C., Carsauw H. Epidemiology of nosocomial bloodstream infections in Belgium, 1992–1996. Eur J Clin Microbiol Infect Dis 1998; 17(10):695-700.
  • 8. Grillot R. Epidemiological survey of candidemia in Europe. Mycology Newsletter 1997; 1:11-4.
  • 9. Edwards J.E., Bodey G.P., Bowden R.A., et al. International conference for the development of a consensus on the managements and prevention of severe candidal infections. Clin Infect Dis 1997; 25:43-59.
  • 10. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice Guidelines for the Treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
  • 11. Nguyen M.H., Peacock J.E., Tanner D.C., et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429-35.
  • 12. Tortorano A.M., Viviani M.A., Rigoni A.L., et al. ECMM survey of candidemia in Europe: Report from Italy. Abstract P5-035. Rev Iberoam Micol 2000; 17:S143.
  • 13. Grillot R., Faure O., Fruit J., et al. Working group: ECMM prospective epidemiological survey of candidemia in Europe: Report from France (682 cases). Abstract P5-036. Rev Iberoam Micol 2000; 17:S144.
  • 14. Klingspor L., Tornquist E., Johansson A., Petrini B., Forsum U., Hedin G. ECMM’s survey of candidemia in Europe: Report from Sweden. Abstract P5-044. Rev Iberoam Micol 2000; 17:S147.
  • 15. Ainscough S., Barnes R., Gant V., et al. Blood stream infections due to Candida species in England and Wales: Data from the ECMM epidemiological survey of candidemia in Europe. Abstract P5-032. Rev Iberoam Micol 2000; 17:S143.
  • 16. Bernhardt H., Zimmermann K., Sissolak D., et al. Epidemiological survey on candidemia in Europe: Results of Germany and Austria. Abstract P5-043. Rev Iberoam Micol 2000; 17:S146.
  • 17. Peman J., Cercos A., Penalver M.C., et al. Epidemiological survey of candidemia in Spain. Abstract P5-033. Rev Iberoam Micol 2000; 17:S143.
  • 18. Anaissie E.J., Rex J.H., Uzun O., Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238-45.
  • 19. Coleman D.C., Rinaldi M.G., Haynes K.A., et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998; 36:156-65.
  • 20. Rex J.H., Bennett J.E., Sugar A.M., et al. Intravascular catheter exchanges and the duration of candidemia. Clin Infect Dis 1995; 21:994-6.
  • 21. Kontoyiannis D.P., Bodey G.P., Mantzoros C.S. Fluconazole vs. amphotericin B for the management of candidemia in adults: a meta-analysis. Mycoses 2001; 44 (5):125-35.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared